Editorial: Making gene therapy for osteosarcoma a reality

Expert Review of Anticancer Therapy

Volumn 10, Issue 4, 2010, Pages 477-480

  Broadhead, Matthew L ^a   Clark, Jonathan Cm ^a,b   Choong, Peter Fm ^a,b   Dass, Crispin R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; DOXORUBICIN; DZ13 ENZYME; INTERLEUKIN 12; NANOPARTICLE; PIGMENT EPITHELIUM DERIVED FACTOR; POLYETHYLENEIMINE; PROTEIN P53; PROTEIN P63; PROTEIN P73; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; CANCER GROWTH; EDITORIAL; GENETIC DISORDER; HUMAN; LUNG METASTASIS; METASTASIS; NONHUMAN; NONVIRAL GENE THERAPY; OSTEOSARCOMA; PATHOGENESIS; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; BONE TUMOR; DISEASE COURSE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETICS; METHODOLOGY; PATHOLOGY;

ANIMALS; BONE NEOPLASMS; DISEASE PROGRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASM METASTASIS; OSTEOSARCOMA;

EID: 77951249808     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.18     Document Type: Editorial

References (52)

1. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res. 466(9), 2114-2130 (2008).
2. Guise TA, O'Keefe R, Randall RL, Terek RM. Molecular biology and therapeutics in musculoskeletal oncology. J. Bone Joint Surg. Am. 91(3), 724-732 (2009).
3. Tan ML, Choong PF, Dass CR. Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol. Ther. 8(2), 106-117 (2009).
4. Canale ST, Beaty JH. Campbell's Operative Orthopaedics. Mosby Elsevier, NY, USA (2008).
5. Dass CR, Choong PF. Gene therapy for osteosarcoma: steps towards clinical studies. J. Pharm. Pharmacol. 60(4), 405-413 (2008).
6. Walkley CR, Qudsi R, Sankaran VG et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 22(12), 1662-1676 (2008). (Pubitemid 351846845)
7. Paulino AC, Fowler BZ. Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr. Hematol. Oncol. 22(2), 89-101 (2005).
8. Libshitz HI, Cohen MA. Radiation-induced osteochondromas. Radiology 142(3), 643-647 (1982).
9. Bovee JV, Sakkers RJ, Geirnaerdt MJ, Taminiau AH, Hogendoorn PC. Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses. J. Clin. Pathol. 55(3), 226-229 (2002).
10. Rani AS, Kumar S. Transformation of non-tumorigenic osteoblast-like human osteosarcoma cells by hexavalent chromates: alteration of morphology, induction of anchorage-independence and proteolytic function. Carcinogenesis 13(11), 2021-2027 (1992).
11. Dutra FR, Largent EJ. Osteosarcoma induced by beryllium oxide. Am. J. Pathol. 26(2), 197-209 (1950).
12. Mazabraud A. [Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium]. Bulletin du Cancer 62(1), 49-58 (1975).
13. Longhi A, Benassi MS, Molendini L, Macchiagodena M, Picci P, Bacci G. Osteosarcoma in blood relatives. Oncol. Rep. 8(1), 131-136 (2001). (Pubitemid 33758215)
14. Iida K, Nobori T, Matsumine A et al. Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines. Oncol. Rep. 10(6), 1961-1965 (2003).
15. Ternovoi VV, Curiel DT, Smith BF, Siegal GP. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab. Invest. 86(8), 748-766 (2006). (Pubitemid 44100475)
16. Oshima Y, Sasaki Y, Negishi H et al. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol. Ther. 6(7), 1058-1066 (2007). (Pubitemid 351574957)
17. Wu JX, Carpenter PM, Gresens C et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5(7), 989-1000 (1990). (Pubitemid 20220240)
18. Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch. 432(6), 515-519 (1998). (Pubitemid 28297558)
19. Beedles KE, Sharpe PT, Wagner EF, Grigoriadis AE. A putative role for c-fos in the pathophysiology of Paget's disease. J. Bone Miner. Res. 14(Suppl. 2), 21-28 (1999). (Pubitemid 29455794)
20. Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55(24), 6244-6251 (1995).
21. Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J. Microencapsul. 25(6), 421-425 (2008).
22. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit. Rev. Oncol. Hematol. 46(2), 165-186 (2003). (Pubitemid 36452345)
23. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol. Med. 10(5), 201-204 (2004).
24. Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10(2), 182-186 (2004). (Pubitemid 38524889)
25. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin. Orthop. Relat. Res. (415 Suppl.), S46-S58 (2003).
26. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1), 33-39 (2007). (Pubitemid 46001467)
27. Choong PF, Fernö M, Akerman M et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer 69(4), 268-272 (1996). (Pubitemid 26298289)
28. Dass CR, Nadesapillai AP, Robin D et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin. Exp. Metastasis 22(8), 643-652 (2005). (Pubitemid 44259525)
29. Dass CR, Choong PF. uPAR mediates anticancer activity of PEDF. Cancer Biol. Ther. 7(8), 1262-1270 (2008).
30. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol. Med. 12(10), 497-502 (2006). (Pubitemid 44468197)
31. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther. 14(7), 616-626 (2007). (Pubitemid 46912035)
32. Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 30(27), 4815-4823 (2009).
33. Tack F, Bakker A, Maes S et al. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J. Drug Target 14(2), 69-86 (2006).
34. Kaiser J. Clinical trials. Gene transfer an unlikely contributor to patient's death. Science 318(5856), 1535 (2007). (Pubitemid 350233636)
35. Kaiser J. Gene therapy. Questions remain on cause of death in arthritis trial. Science 317(5845), 1665 (2007). (Pubitemid 47461809)
36. Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science 317(5838), 580 (2007).
37. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132(1-2), 1-14 (2008). (Pubitemid 351232078)
38. Thrasher AJ, Gaspar HB, Baum C et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 443(7109), E5-6 (2006). (Pubitemid 44435140)
39. Kaiser J. Gene therapy. Panel urges limits on X-SCID trials. Science 307(5715), 1544-1545 (2005).
40. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol. Ther. 4(5), 512-517 (2005). (Pubitemid 41351222)
41. Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res. 143(2), 184-194 (2009).
42. Carette JE, Graat HC, Schagen FH et al. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology 361(1), 56-67 (2007).
43. Barnett BG, Tillman BW, Curiel DT, Douglas JT. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol. Ther. 6(3), 377-385 (2002).
44. Murofushi Y, Nagano S, Kamizono J et al. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. Int. J. Oncol. 29(3), 681-688 (2006).
45. Dass CR, Choong PF. Non-viral methods for gene transfer towards osteosarcoma therapy. J. Drug Target 15(3), 184-189 (2007).
46. Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev. Anticancer Ther. 6(2), 225-237 (2006).
47. Worth LL, Jia SF, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res. 6(9), 3713-3718 (2000).
48. Densmore CL, Kleinerman ES, Gautam A et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8(9), 619-627 (2001). (Pubitemid 32912235)
49. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 9(3), 260-266 (2002). (Pubitemid 34205500)
50. Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin. Cancer Res. 9(9), 3462-3468 (2003). (Pubitemid 37082745)
51. Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106(6), 1382-1388 (2006). (Pubitemid 43363918)
52. Ta HT, Dass CR, Dunstan DE. Injectable chitosan hydrogels for localised cancer therapy. J. Control Release 126(3), 205-216 (2008).